Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The pharmacokinetics and bioavailability of pamidronate were assessed in patients with breast cancer, 6 subjects received the drug intravenously and 7 orally. The initial plasma half-life of pamidronate was short (42±27 min) and the apparent total plasma clearance was high (471±298 ml/min). The renal clearance (74±34 ml/min) was similar to the creatinine clearance (66±19 ml/min). Most of the renal elimination occurred during and immediately post a 4 h infusion of the drug (23.2±7.9% in 24h). The non-renal clearance was ascribed to uptake by bone and deep tissue compartments. Little additional drug appeared in the urine after 24 h. The mean bioavailability was estimated using a parallel study design to be 0.3% for a 300 mg oral dose. © 1991 Springer-Verlag.

Original publication

DOI

10.1007/BF02555856

Type

Journal article

Journal

Calcified Tissue International

Publication Date

01/11/1991

Volume

49

Pages

433 - 435